Related references
Note: Only part of the references are listed.Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Joel Guigay et al.
LANCET ONCOLOGY (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.
Majd Issa et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes
Petr Szturz et al.
ONCOLOGIST (2021)
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shinsuke Suzuki et al.
MEDICINA-LITHUANIA (2021)
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
Morena Fasano et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study
Viktor Gruenwald et al.
ORAL ONCOLOGY (2020)
TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Joel Guigay et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Translating KEYNOTE-048 into practice recommendations for head and neck cancer
Petr Szturz et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Athanassios Argiris et al.
FRONTIERS IN ONCOLOGY (2017)
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
R. Mesia et al.
ANNALS OF ONCOLOGY (2010)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
